Reducing breast cancer recurrence may significantly lower cost of care
Published in Oncology Business Week, July 2nd, 2006
Researchers at the Henry Ford Health System in Detroit report, "The economics of breast cancer recurrence are poorly understood. For this retrospective cohort study, we evaluated the economic burden of breast cancer recurrence by using data from a large Midwestern healthcare system."
L. Lamerato and colleagues described their study: "Women with Stage I or II breast cancer (according to the American Joint Commission on Cancer staging criteria) were identified from the tumor registry of the Henry Ford Health System. The economic burden of breast cancer recurrence was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- BSD Medical Corp.
BSD Medical receives order for cancer treatment systems in China - Breast Cancer
Better survival seen for early breast cancer patients switched from tamoxifen to aromasin - Cancer Therapy
Follow-up study of imatinib shows excellent results as treatment for chronic myelogenous leukemia - Centocor, U.S.
Studies from the United States and Japan describe new findings in cancer treatment research - Colon Cancer
Colorectal cancer screening costs discussed - Covance Inc.
Covance expands its antibody products and services with acquisition of Signet Laboratories - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
